

LITERATURA

1. Heestermans M, et al. Anticoagulants: A Short History, Their Mechanism of Action, Pharmacology, and Indications. *Cells* 2022; 11(20): 3214.
2. Kholmukhamedov A, et al. Anticoagulation Management: Current Landscape and Future Trends. *J Clin Med* 2025; 14(5): 1647.
3. SmPC Heparin Léčiva. Dostupné na: www.sukl.gov.cz
4. SmPC Clexane. Dostupné na: www.sukl.gov.cz
5. SmPC Fraxiparine. Dostupné na: www.sukl.gov.cz
6. SmPC Arixtra. Dostupné na: www.ema.europa.eu
7. Schindewolf M, et al. Use of Fondaparinux Off-Label or Approved Anticoagulants for Management of Heparin-Induced Thrombocytopenia. *J Am Coll Cardiol*. 2017; 70(21): 2636–2648.
8. Trautmann A, et al. Delayed-Type Heparin Allergy: Intravenous Tolerance Despite Inflammatory Skin Reaction After Subcutaneous Injection. *J Allergy Clin Immunol Pract*. 2022; 10(11): 2977–2983.
9. SmPC Warfarin Orion. Dostupné na: www.sukl.gov.cz
10. Yeh CH, et al. Overview of the new oral anticoagulants: opportunities and challenges. *Arterioscler Thromb Vasc Biol* 2015; 35(5): 1056–1065.
11. Karetová D, Bultas J. Léky užívané k profylaxi a léčbě tromboembolické nemoci. V: *Farmakoterapie tromboembolických stavů*, Maxdorf 2013: s. 42–119.
12. SmPC Pradaxa. Dostupné na: www.sukl.gov.cz
13. SmPC Xarelto. Dostupné na: www.sukl.gov.cz
14. SmPC Eliquis. Dostupné na: www.sukl.gov.cz
15. SmPC Lixiana. Dostupné na: www.sukl.gov.cz
16. Bertolotti L, et al. Direct oral anticoagulants: Current indications and unmet needs in the treatment of venous thromboembolism. *Pharmacol Res* 2017; 118: 33–42.
17. Tomaselli GF, et al. 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Solution Set Oversight Committee. *J Am Coll Cardiol* 2020; 76(5): 594–622.
18. Harrington J, et al. Clinical Evaluation of Factor XIa Inhibitor Drugs: JACC Review Topic of the Week. *J Am Coll Cardiol* 2023; 81(8): 771–779.
19. Douketis JD, Spyropoulos AC. Perioperative Management of Patients Taking Direct Oral Anticoagulants: A Review. *JAMA* 2024; 332(10): 825–834. Erratum in: *JAMA* 2024; 332(15): 1306.
20. Rao SV, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation* 2025; 151(13): e771–e862.
21. Falanga A, et al; ESMO Guidelines Committee. Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline. *Ann Oncol* 2023; 34(5): 452–467.
22. Goulart TO, et al. Intracranial Hemorrhage With Direct Oral Anticoagulants vs Low-Molecular-Weight Heparin in Brain Tumors: A Review and Meta-Analysis. *Neurology* 2025; 105(8): e214140.
23. Patel JP, et al. Progress in the monitoring of direct oral anticoagulant therapy. *Br J Haematol* 2019; 184(6): 912–924.
24. Khan F, et al. Predictors of recurrent venous thromboembolism and bleeding in patients with cancer: a meta-analysis. *Eur Heart J* 2025; doi:10.1093/eurheartj/ehaf453.
25. Van Gelder IC, et al.; ESC Scientific Document Group. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). *Eur Heart J* 2024; 45(36): 3314–3414.
26. Olie RH, Winckers K, Rocca B, Ten Cate H. Oral Anticoagulants Beyond Warfarin. *Annu Rev Pharmacol Toxicol*. 2024; 64: 551–575.
27. Mithoowani S, Siegal D. DOACs: role of anti-Xa and drug level monitoring. *Hematology Am Soc Hematol Educ Program* 2024; 2024(1): 178–185.